Emerging migraine treatments and drug targets

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Emerging migraine treatments and drug targets. / Olesen, Jes; Ashina, Messoud.

I: Trends in Pharmacological Sciences, Bind 32, Nr. 6, 2011, s. 352-9.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Olesen, J & Ashina, M 2011, 'Emerging migraine treatments and drug targets', Trends in Pharmacological Sciences, bind 32, nr. 6, s. 352-9. https://doi.org/10.1016/j.tips.2011.02.016

APA

Olesen, J., & Ashina, M. (2011). Emerging migraine treatments and drug targets. Trends in Pharmacological Sciences, 32(6), 352-9. https://doi.org/10.1016/j.tips.2011.02.016

Vancouver

Olesen J, Ashina M. Emerging migraine treatments and drug targets. Trends in Pharmacological Sciences. 2011;32(6):352-9. https://doi.org/10.1016/j.tips.2011.02.016

Author

Olesen, Jes ; Ashina, Messoud. / Emerging migraine treatments and drug targets. I: Trends in Pharmacological Sciences. 2011 ; Bind 32, Nr. 6. s. 352-9.

Bibtex

@article{cf01b07809964204ac98c27dff552550,
title = "Emerging migraine treatments and drug targets",
abstract = "Migraine has a 1-year prevalence of 10% and high socioeconomic costs. Despite recent drug developments, there is a huge unmet need for better pharmacotherapy. In this review we discuss promising anti-migraine strategies such as calcitonin gene-related peptide (CGRP) receptor antagonists and 5-hydroxytrypamine (5-HT)(1F) receptor agonists, which are in late-stage development. Nitric oxide antagonists are also in development. New forms of administration of sumatriptan might improve efficacy and reduce side effects. Botulinum toxin A has recently been approved for the prophylaxis of chronic migraine. Tonabersat, a cortical spreading depression inhibitor, has shown efficacy in the prophylaxis of migraine with aura. Several new drug targets such as nitric oxide synthase, the 5-HT(1D) receptor, the prostanoid receptors EP(2) and EP(4), and the pituitary adenylate cyclase receptor PAC1 await development. The greatest need is for new prophylactic drugs, and it seems likely that such compounds will be developed in the coming decade.",
author = "Jes Olesen and Messoud Ashina",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
doi = "http://dx.doi.org/10.1016/j.tips.2011.02.016",
language = "English",
volume = "32",
pages = "352--9",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Ltd. * Trends Journals",
number = "6",

}

RIS

TY - JOUR

T1 - Emerging migraine treatments and drug targets

AU - Olesen, Jes

AU - Ashina, Messoud

N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.

PY - 2011

Y1 - 2011

N2 - Migraine has a 1-year prevalence of 10% and high socioeconomic costs. Despite recent drug developments, there is a huge unmet need for better pharmacotherapy. In this review we discuss promising anti-migraine strategies such as calcitonin gene-related peptide (CGRP) receptor antagonists and 5-hydroxytrypamine (5-HT)(1F) receptor agonists, which are in late-stage development. Nitric oxide antagonists are also in development. New forms of administration of sumatriptan might improve efficacy and reduce side effects. Botulinum toxin A has recently been approved for the prophylaxis of chronic migraine. Tonabersat, a cortical spreading depression inhibitor, has shown efficacy in the prophylaxis of migraine with aura. Several new drug targets such as nitric oxide synthase, the 5-HT(1D) receptor, the prostanoid receptors EP(2) and EP(4), and the pituitary adenylate cyclase receptor PAC1 await development. The greatest need is for new prophylactic drugs, and it seems likely that such compounds will be developed in the coming decade.

AB - Migraine has a 1-year prevalence of 10% and high socioeconomic costs. Despite recent drug developments, there is a huge unmet need for better pharmacotherapy. In this review we discuss promising anti-migraine strategies such as calcitonin gene-related peptide (CGRP) receptor antagonists and 5-hydroxytrypamine (5-HT)(1F) receptor agonists, which are in late-stage development. Nitric oxide antagonists are also in development. New forms of administration of sumatriptan might improve efficacy and reduce side effects. Botulinum toxin A has recently been approved for the prophylaxis of chronic migraine. Tonabersat, a cortical spreading depression inhibitor, has shown efficacy in the prophylaxis of migraine with aura. Several new drug targets such as nitric oxide synthase, the 5-HT(1D) receptor, the prostanoid receptors EP(2) and EP(4), and the pituitary adenylate cyclase receptor PAC1 await development. The greatest need is for new prophylactic drugs, and it seems likely that such compounds will be developed in the coming decade.

U2 - http://dx.doi.org/10.1016/j.tips.2011.02.016

DO - http://dx.doi.org/10.1016/j.tips.2011.02.016

M3 - Review

VL - 32

SP - 352

EP - 359

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 6

ER -

ID: 40140742